Literature DB >> 3499953

Complement depletion suppresses Lewis rat experimental allergic neuritis.

T E Feasby1, J J Gilbert, A F Hahn, M Neilson.   

Abstract

Lewis rats immunized with myelin and complete Freund's adjuvant were treated with cobra venom factor (CVF) which depletes the C3 component of complement. CVF given at day 9 delayed the onset of experimental allergic neuritis (EAN) by 2-3 days and when given at days 9 and 12 delayed the onset of EAN by 4-5 days. Lumbar nerve roots of CVF-treated rats had significantly less demyelination than those from control EAN rats.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3499953     DOI： 10.1016/0006-8993(87)90572-5

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  9 in total

1.  Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration.

Authors:  A T Dailey; A M Avellino; L Benthem; J Silver; M Kliot
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

Review 2.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

3.  P2-peptide induced experimental allergic neuritis: a model to study axonal degeneration.

Authors:  A F Hahn; T E Feasby; L Wilkie; D Lovgren
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro.

Authors:  W Brück; Y Brück; U Diederich; S J Piddlesden
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 5.  Guillain-Barré syndrome: clinical and immunological aspects.

Authors:  A M Rostami
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies.

Authors:  Luis A Querol; Hans-Peter Hartung; Richard A Lewis; Pieter A van Doorn; Timothy R Hammond; Nazem Atassi; Miguel Alonso-Alonso; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-04-04       Impact factor: 6.088

Review 7.  The role of the complement system in Multiple Sclerosis: A review.

Authors:  Nil Saez-Calveras; Olaf Stuve
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 8.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 9.  Therapeutic uses of recombinant complement protein inhibitors.

Authors:  K R Kalli; P Hsu; D T Fearon
Journal:  Springer Semin Immunopathol       Date:  1994
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.